{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:12:40Z","timestamp":1792552360620,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172654"],"award-info":[{"award-number":["82172654"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002767","name":"Hunan Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["2021RC4012"],"award-info":[{"award-number":["2021RC4012"]}],"id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-025-07490-5","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T15:53:33Z","timestamp":1738079613000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Characterization of Bozitinib as a potential therapeutic agent for MET-amplified gastric cancer"],"prefix":"10.1038","volume":"8","author":[{"given":"Hang","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhi","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2072-2169","authenticated-orcid":false,"given":"Hudie","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianmeng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huajun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8484-634X","authenticated-orcid":false,"given":"Shuyan","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8139-6892","authenticated-orcid":false,"given":"Yongheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"7490_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/311029a0","volume":"311","author":"CS Cooper","year":"1984","unstructured":"Cooper, C. S. et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311, 29\u201333 (1984).","journal-title":"Nature"},{"key":"7490_CR2","doi-asserted-by":"publisher","first-page":"6379","DOI":"10.1073\/pnas.84.18.6379","volume":"84","author":"M Park","year":"1987","unstructured":"Park, M. et al. Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc. Natl Acad. Sci. USA 84, 6379\u20136383 (1987).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"7490_CR3","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1126\/science.1846706","volume":"251","author":"DP Bottaro","year":"1991","unstructured":"Bottaro, D. P. et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251, 802\u2013804 (1991).","journal-title":"Science"},{"key":"7490_CR4","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/nrm3012","volume":"11","author":"L Trusolino","year":"2010","unstructured":"Trusolino, L., Bertotti, A. & Comoglio, P. M. MET signalling: principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell Biol. 11, 834\u2013848 (2010).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"7490_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrc3205","volume":"12","author":"E Gherardi","year":"2012","unstructured":"Gherardi, E., Birchmeier, W., Birchmeier, C. & Woude, Vande G. Targeting MET in cancer: rationale and progress. Nat. Rev. Cancer 12, 89\u2013103 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"7490_CR6","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/2159-8290.CD-19-1446","volume":"10","author":"G Recondo","year":"2020","unstructured":"Recondo, G., Che, J., J\u00e4nne, P. A. & Awad, M. M. Targeting MET dysregulation in cancer. Cancer Discov. 10, 922\u2013934 (2020).","journal-title":"Cancer Discov."},{"key":"7490_CR7","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1177\/1758834011422556","volume":"3","author":"SL Organ","year":"2011","unstructured":"Organ, S. L. & Tsao, M. S. An overview of the c-MET signaling pathway. Ther. Adv. Med Oncol. 3, S7\u2013s19 (2011).","journal-title":"Ther. Adv. Med Oncol."},{"key":"7490_CR8","doi-asserted-by":"publisher","first-page":"7670","DOI":"10.1021\/acs.jmedchem.3c00028","volume":"66","author":"C Wang","year":"2023","unstructured":"Wang, C. & Lu, X. Targeting MET: Discovery of small molecule inhibitors as non-small cell lung cancer therapy. J. Med Chem. 66, 7670\u20137697 (2023).","journal-title":"J. Med Chem."},{"key":"7490_CR9","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1038\/s41388-021-01863-w","volume":"40","author":"J Fu","year":"2021","unstructured":"Fu, J. et al. HGF\/c-MET pathway in cancer: from molecular characterization to clinical evidence. Oncogene 40, 4625\u20134651 (2021).","journal-title":"Oncogene"},{"key":"7490_CR10","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1158\/1078-0432.CCR-19-3608","volume":"26","author":"G Recondo","year":"2020","unstructured":"Recondo, G. et al. Molecular mechanisms of acquired resistance to MET Tyrosine Kinase inhibitors in patients with MET Exon 14-mutant NSCLC. Clin. Cancer Res 26, 2615\u20132625 (2020).","journal-title":"Clin. Cancer Res"},{"key":"7490_CR11","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.canlet.2016.07.021","volume":"380","author":"P Shi","year":"2016","unstructured":"Shi, P. et al. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer Lett. 380, 494\u2013504 (2016).","journal-title":"Cancer Lett."},{"key":"7490_CR12","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1158\/0008-5472.CAN-10-1623","volume":"71","author":"J Qi","year":"2011","unstructured":"Qi, J. et al. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res 71, 1081\u20131091 (2011).","journal-title":"Cancer Res"},{"key":"7490_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13045-019-0759-9","volume":"12","author":"Q Wang","year":"2019","unstructured":"Wang, Q., Yang, S., Wang, K. & Sun, S. Y. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. J. Hematol. Oncol. 12, 63 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"7490_CR14","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jtho.2022.10.015","volume":"18","author":"J Remon","year":"2023","unstructured":"Remon, J. et al. MET alterations in NSCLC-current perspectives and future challenges. J. Thorac. Oncol. 18, 419\u2013435 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"7490_CR15","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s40265-020-01347-3","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon, S. Capmatinib: First approval. Drugs 80, 1125\u20131131 (2020).","journal-title":"Drugs"},{"key":"7490_CR16","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s40265-020-01317-9","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham, A. Tepotinib: First approval. Drugs 80, 829\u2013833 (2020).","journal-title":"Drugs"},{"key":"7490_CR17","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1007\/s40265-021-01584-0","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham, A. Savolitinib: First approval. Drugs 81, 1665\u20131670 (2021).","journal-title":"Drugs"},{"key":"7490_CR18","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.ejmech.2017.08.044","volume":"143","author":"PK Parikh","year":"2018","unstructured":"Parikh, P. K. & Ghate, M. D. Recent advances in the discovery of small molecule c-Met Kinase inhibitors. Eur. J. Med. Chem. 143, 1103\u20131138 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"7490_CR19","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa2002787","volume":"383","author":"J Wolf","year":"2020","unstructured":"Wolf, J. et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N. Engl. J. Med. 383, 944\u2013957 (2020).","journal-title":"N. Engl. J. Med."},{"key":"7490_CR20","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1016\/j.annonc.2022.02.035","volume":"33","author":"J Wolf","year":"2022","unstructured":"Wolf, J. et al. 26P Capmatinib in treatment (Tx)-naive MET exon 14-mutated (METex14) advanced non-small cell lung Cancer (aNSCLC): Updated results from GEOMETRY mono-1. Ann. Oncol. 33, S42 (2022).","journal-title":"Ann. Oncol."},{"key":"7490_CR21","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1001\/jamaoncol.2023.1962","volume":"9","author":"J Mazieres","year":"2023","unstructured":"Mazieres, J. et al. Tepotinib treatment in patients with MET Exon 14-skipping non-small cell lung cancer: long-term follow-up of the VISION Phase 2 nonrandomized clinical trial. JAMA Oncol. 9, 1260\u20131266 (2023).","journal-title":"JAMA Oncol."},{"key":"7490_CR22","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/S2213-2600(21)00084-9","volume":"9","author":"S Lu","year":"2021","unstructured":"Lu, S. et al. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. Lancet Respir. Med. 9, 1154\u20131164 (2021).","journal-title":"Lancet Respir. Med."},{"key":"7490_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101952","volume":"59","author":"Y Yu","year":"2023","unstructured":"Yu, Y. et al. Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b\/2 trial. EClinicalMedicine 59, 101952 (2023).","journal-title":"EClinicalMedicine"},{"key":"7490_CR24","doi-asserted-by":"publisher","first-page":"S791","DOI":"10.1016\/j.annonc.2023.09.2412","volume":"34","author":"JJ Yang","year":"2023","unstructured":"Yang, J. J. et al. 1379P Preliminary results of phase II KUNPENG study of vebreltinib in patients (Pts) with advanced NSCLC harboring c-MET alterations. Ann. Oncol. 34, S791 (2023).","journal-title":"Ann. Oncol."},{"key":"7490_CR25","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.cell.2018.09.038","volume":"175","author":"H Hu","year":"2018","unstructured":"Hu, H. et al. Mutational landscape of secondary Glioblastoma Guides MET-targeted trial in brain tumor. Cell 175, 1665\u20131678.e1618 (2018).","journal-title":"Cell"},{"key":"7490_CR26","doi-asserted-by":"publisher","first-page":"CT127","DOI":"10.1158\/1538-7445.AM2020-CT127","volume":"80","author":"J Yang","year":"2020","unstructured":"Yang, J. et al. Abstract CT127: A phase I study of cMET inhibitor bozitinib in patients with advanced NSCLC harboring cMET alterations. Cancer Res. 80, CT127 (2020).","journal-title":"Cancer Res."},{"key":"7490_CR27","doi-asserted-by":"publisher","first-page":"3680","DOI":"10.1200\/JCO.23.02363","volume":"42","author":"JJ Yang","year":"2024","unstructured":"Yang, J. J. et al. Vebreltinib for advanced non-small cell lung cancer harboring c-Met Exon 14 skipping mutation: a multicenter, single-arm, Phase II KUNPENG Study. J. Clin. Oncol. 42, 3680\u20133691 (2024).","journal-title":"J. Clin. Oncol."},{"key":"7490_CR28","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1038\/modpathol.2013.108","volume":"26","author":"SY Ha","year":"2013","unstructured":"Ha, S. Y. et al. MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. Mod. Pathol. 26, 1632\u20131641 (2013).","journal-title":"Mod. Pathol."},{"key":"7490_CR29","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/cncr.30437","volume":"123","author":"DV Catenacci","year":"2017","unstructured":"Catenacci, D. V. et al. MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma. Cancer 123, 1061\u20131070 (2017).","journal-title":"Cancer"},{"key":"7490_CR30","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1080\/028418601750444204","volume":"40","author":"TJ Huang","year":"2001","unstructured":"Huang, T. J., Wang, J. Y., Lin, S. R., Lian, S. T. & Hsieh, J. S. Overexpression of the c-met protooncogene in human gastric carcinoma-correlation to clinical features. Acta Oncol. 40, 638\u2013643 (2001).","journal-title":"Acta Oncol."},{"key":"7490_CR31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.canlet.2015.05.028","volume":"365","author":"L Marano","year":"2015","unstructured":"Marano, L. et al. c-Met targeting in advanced gastric cancer: An open challenge. Cancer Lett. 365, 30\u201336 (2015).","journal-title":"Cancer Lett."},{"key":"7490_CR32","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1021\/acsmedchemlett.9b00276","volume":"10","author":"GW Collie","year":"2019","unstructured":"Collie, G. W. et al. Structural and molecular insight into resistance mechanisms of first generation cMET inhibitors. ACS Med Chem. Lett. 10, 1322\u20131327 (2019).","journal-title":"ACS Med Chem. Lett."},{"key":"7490_CR33","doi-asserted-by":"publisher","first-page":"6342","DOI":"10.1021\/jm2007613","volume":"54","author":"JJ Cui","year":"2011","unstructured":"Cui, J. J. et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J. Med Chem. 54, 6342\u20136363 (2011).","journal-title":"J. Med Chem."},{"key":"7490_CR34","doi-asserted-by":"publisher","unstructured":"Wang, C. et al. Structural basis of diverse membrane target recognitions by ankyrins. Elife 3, https:\/\/doi.org\/10.7554\/eLife.04353 (2014).","DOI":"10.7554\/eLife.04353"},{"key":"7490_CR35","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.jtho.2019.06.023","volume":"14","author":"T Fujino","year":"2019","unstructured":"Fujino, T. et al. Sensitivity and resistance of MET Exon 14 mutations in lung cancer to eight MET Tyrosine Kinase inhibitors in vitro. J. Thorac. Oncol. 14, 1753\u20131765 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"7490_CR36","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris, G. M. et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput Chem. 30, 2785\u20132791 (2009).","journal-title":"J. Comput Chem."},{"key":"7490_CR37","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ctrv.2017.10.003","volume":"61","author":"YL Wu","year":"2017","unstructured":"Wu, Y. L. et al. Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer? Cancer Treat. Rev. 61, 70\u201381 (2017).","journal-title":"Cancer Treat. Rev."},{"key":"7490_CR38","doi-asserted-by":"publisher","unstructured":"Kim, J. S., Kim, M. Y. & Hong, S. Characterization of MET Alterations in 37 Gastroesophageal Cancer Cell Lines for MET-Targeted Therapy. Int. J. Mol. Sci. 25, https:\/\/doi.org\/10.3390\/ijms25115975 (2024).","DOI":"10.3390\/ijms25115975"},{"key":"7490_CR39","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.tranon.2018.12.009","volume":"12","author":"ST Kim","year":"2019","unstructured":"Kim, S. T. et al. Combination of Docetaxel Plus Savolitinib in refractory cancer patients: a report on Phase I Trial. Transl. Oncol. 12, 597\u2013601 (2019).","journal-title":"Transl. Oncol."},{"key":"7490_CR40","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1158\/2159-8290.CD-19-0442","volume":"9","author":"J Lee","year":"2019","unstructured":"Lee, J. et al. Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: The VIKTORY Umbrella Trial. Cancer Discov. 9, 1388\u20131405 (2019).","journal-title":"Cancer Discov."},{"key":"7490_CR41","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/j.bmcl.2015.02.002","volume":"25","author":"D Dorsch","year":"2015","unstructured":"Dorsch, D. et al. Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors. Bioorg. Med Chem. Lett. 25, 1597\u20131602 (2015).","journal-title":"Bioorg. Med Chem. Lett."},{"key":"7490_CR42","doi-asserted-by":"publisher","first-page":"5712","DOI":"10.1016\/j.csbj.2023.11.028","volume":"21","author":"L Qu","year":"2023","unstructured":"Qu, L. et al. Structural insight into the macrocyclic inhibitor TPX-0022 of c-Met and c-Src. Comput Struct. Biotechnol. J. 21, 5712\u20135718 (2023).","journal-title":"Comput Struct. Biotechnol. J."},{"key":"7490_CR43","doi-asserted-by":"publisher","first-page":"26281","DOI":"10.18632\/oncotarget.15457","volume":"8","author":"J Du","year":"2017","unstructured":"Du, J. et al. Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification. Oncotarget 8, 26281\u201326287 (2017).","journal-title":"Oncotarget"},{"key":"7490_CR44","doi-asserted-by":"publisher","unstructured":"Frigault, M. M. et al. Mechanisms of acquired resistance to Savolitinib, a selective MET Inhibitor in MET-amplified gastric cancer. JCO Precis. Oncol. 4, https:\/\/doi.org\/10.1200\/po.19.00386 (2020).","DOI":"10.1200\/po.19.00386"},{"key":"7490_CR45","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13045-022-01299-z","volume":"15","author":"T Fujino","year":"2022","unstructured":"Fujino, T. et al. Foretinib can overcome common on-target resistance mutations after capmatinib\/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation. J. Hematol. Oncol. 15, 79 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"7490_CR46","doi-asserted-by":"publisher","first-page":"6661","DOI":"10.1158\/1078-0432.CCR-17-1192","volume":"23","author":"LD Engstrom","year":"2017","unstructured":"Engstrom, L. D. et al. Glesatinib exhibits antitumor activity in lung cancer models and patients harboring MET Exon 14 mutations and overcomes mutation-mediated resistance to Type I MET inhibitors in nonclinical models. Clin. Cancer Res 23, 6661\u20136672 (2017).","journal-title":"Clin. Cancer Res"},{"key":"7490_CR47","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1107\/S0907444909047337","volume":"66","author":"W Kabsch","year":"2010","unstructured":"Kabsch, W. XDS. Acta Crystallogr. D. Biol. Crystallogr 66, 125\u2013132 (2010).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr"},{"key":"7490_CR48","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1107\/S2059798319011471","volume":"75","author":"D Liebschner","year":"2019","unstructured":"Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr D. Struct. Biol. 75, 861\u2013877 (2019).","journal-title":"Acta Crystallogr D. Struct. Biol."},{"key":"7490_CR49","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ymeth.2011.07.005","volume":"55","author":"PD Adams","year":"2011","unstructured":"Adams, P. D. et al. The Phenix software for automated determination of macromolecular structures. Methods 55, 94\u2013106 (2011).","journal-title":"Methods"},{"key":"7490_CR50","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1107\/S0907444912001308","volume":"68","author":"PV Afonine","year":"2012","unstructured":"Afonine, P. V. et al. Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr. D. Biol. Crystallogr. 68, 352\u2013367 (2012).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"7490_CR51","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D. Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"7490_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2020.127757","volume":"34","author":"M Guo","year":"2021","unstructured":"Guo, M. et al. Characterization of ibrutinib as a non-covalent inhibitor of SRC-family kinases. Bioorg. Med. Chem. Lett. 34, 127757 (2021).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"7490_CR53","doi-asserted-by":"publisher","first-page":"5.6.1","DOI":"10.1002\/cpbi.3","volume":"54","author":"B Webb","year":"2016","unstructured":"Webb, B. & Sali, A. Comparative protein structure modeling using MODELLER. Curr. Protoc. Bioinforma. 54, 5.6.1\u20135.6.37 (2016).","journal-title":"Curr. Protoc. Bioinforma."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07490-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07490-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07490-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T13:30:24Z","timestamp":1738848624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07490-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7490"],"URL":"https:\/\/doi.org\/10.1038\/s42003-025-07490-5","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"8 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests. Figure\u00a0 is created by Figdraw ().","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"134"}}